BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Nirmal Bang Report
We analysed the translation of research and development and acquisition expenditure to U.S. sales for the top Indian pharmaceutical companies exporting to the U.S. - Lupin Ltd., Aurobindo Pharma Ltd., Cadila Healthcare Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd. and Cipla Ltd.
We see a clear trend of Aurobindo Pharma and Cadila Healthcare managing research and development expenditure more efficiently with higher U.S. sales and higher incremental abbreviated new drug application filings in the U.S. market per dollar of research and development spend.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR